Lv1
70 积分 2022-08-03 加入
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies
6天前
已完结
Treatment Decisions in Multiple Myeloma
6天前
已完结
Practical insights into bispecific antibody therapy in multiple myeloma
7天前
已完结
Survival outcomes comparing sequencing of CAR-T followed by BiTE versus BiTE followed by CAR-T in patients with relapsed multiple myeloma
7天前
已完结
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure
10天前
已完结
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
11天前
已完结
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations
12天前
已完结
Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database
13天前
已完结
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma
14天前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
26天前
已完结
皖公网安备34019202002308
